Berlin - Delayed Quote EUR

Fresenius Medical Care AG & Co. KGaA (FME.BE)

38.81

-0.02

(-0.05%)

As of 8:09 AM GMT+2. Market Open.

Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today published its joint 2023 Annual Report and Non-financial Group Report, available digitally on the corporate website. Titled "Shaping the Future of Kidney Care," the report provides detailed information about Fresenius Medical Care's economic, social and environmental performance in 2023.

PR Newswire last month
Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, launches a new "Augmented Reality" (AR) application to make learning easier for nursing staff in Kidney Replacement Therapy in Intensive Care Units. The AR glasses, in combination with digital learning modules, allow nursing staff to learn how to use acute dialysis machines on site within the intensive care wards. The glasses stream visual and acoustic recordings as users inte

PR Newswire last month
Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the sale of its dialysis clinic networks in Brazil, Colombia, Chile and Ecuador to DaVita Inc. for a total transaction price of USD 300 million. Subject to regulatory approvals in Brazil, Colombia and Ecuador, the transactions represent another milestone in Fresenius Medical Care's portfolio optimization program, with each expected to close throughout 2024.

PR Newswire last month
Fresenius Medical Care delivers on commitments in a year of fundamental transformation

Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "In 2023, we delivered on our commitments while we fundamentally transformed Fresenius Medical Care. Exceeding our upgraded financial outlook for the full year was the very successful finish to an extraordinary year. We implemented the new global operating model, progressed on our operational turnaround ambitions, changed our legal form and advanced on the Portfolio Optimization Program through key divestments. Thanks to the co

PR Newswire 2 months ago
Fresenius Medical Care Brings Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S., demonstrating Global Leadership in Medical Device and Membrane Engineering Technologies

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced the company has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the company's 5008X Hemodialysis System. Now the company wants to bring a new standard of care in dialysis therapy to people living with kidney diseases in the U.S.

PR Newswire 2 months ago
Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee representatives. The judicial appointment will remain effective until completion of the election of employee representatives by the FME workforce located in German

PR Newswire 2 months ago
Fresenius Medical Care Executes on Its Strategic Portfolio Optimization Program and Announces Key Transactions

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced updates from transactions in 2023 as part of the Company's ongoing Portfolio Optimization Program. Refocused on businesses and markets with the best strategic fit and greatest scale and sustainable profitable growth potential, Fresenius Medical Care continues exiting unsustainable markets, divesting noncore and dilutive assets and prioritizing deleveraging as part of

PR Newswire 3 months ago
Fresenius Medical Care completes change of legal form into a German stock corporation

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, announces the successful completion of its change of legal form from a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a German stock corporation (Aktiengesellschaft, AG) as of November 30, 2023. With this important milestone, Fresenius Medical Care is opening a new chapter in the history of the Company with a simplified corporate governance structure tha

PR Newswire 4 months ago
Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million - 2023 earnings outlook raised

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, resolved a legal dispute with the U.S. government, for accounts receivable in legal dispute, and entered into a final and legally binding settlement agreement today, whereby the company will receive a payment from the U.S. government.

PR Newswire 5 months ago
Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months and solid business outlook for the fourth quarter

Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "Our unwavering focus on executing against our strategic plan and the successful implementation of turnaround measures to date, continue to translate into improved operating performance. Notably in the third quarter, we continued to unlock sustainable savings with our FME25 program, further improved our labor productivity and continued to execute on our portfolio optimization plan. Given our improving performance for the first

PR Newswire 5 months ago
Fresenius Medical Care appoints Craig Cordola as new Management Board member for Care Delivery

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has appointed Craig Cordola (52) as new Management Board member for the globally operating Care Delivery segment. Cordola will start on January 1, 2024, as Chief Executive Officer of Care Delivery. He will be based in Waltham, Massachusetts.

PR Newswire 5 months ago
Fresenius Medical Care Demonstrates Commitment to Innovating Dialysis and Kidney Disease Care with Presentations at the American Society of Nephrology (ASN) Kidney Week 2023

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the presentation of over 60 company-affiliated research abstracts at the American Society of Nephrology's (ASN) Kidney Week 2023 taking place November 2-5 in Philadelphia.

PR Newswire 5 months ago
Fresenius Medical Care Achieves Key AI Milestone With First-Phase Completion of Largest Global Dialysis Clinical Dataset

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the phase-one completion of the company's first anonymized global dialysis dataset—coined the Apollo database project—the foundation of the company's long-term AI aspirations. Intended to advance patient care quality and outcomes by making kidney disease care more personalized and precise, the database provides a highly sophisticated view into the clinical care provi

PR Newswire 5 months ago
Capital Square Delivers 149.59% Total Return* to Investors in Medical Building DST

Capital Square, one of the nation's leading sponsors of tax-advantaged real estate investments and an active developer and manager of multifamily communities, announced today the sale of a medical building in Winchester, Virginia. The property was owned by a group of DST investors who realized a 149.09% total return, or a 6.78% annualized return, from their 1031 exchange investment.*

PR Newswire 6 months ago
Capital Square Delivers 147.63% Total Return* to Investors in Medical Building DST

Capital Square, one of the nation's leading sponsors of tax-advantaged real estate investments and an active developer of multifamily communities, announced today the sale of a medical building in Kinston, North Carolina. The property was owned by a group of DST investors who realized 147.63% total return, or a 7.15% annualized return, from their 1031 exchange investment.*

PR Newswire 6 months ago
Fresenius Medical Care Announces FDA Clearance of Versi®HD with GuideMe Software

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, today announced the U.S. Food and Drug Administration (FDA) 510(k) clearance for Versi®HD with GuideMe Software, a completely reinvented self-guided interface for the company's VersiHD chronic home hemodialysis (HHD) system. VersiHD with GuideMe Software aims to transform the experience of HHD for patients and nurses.

PR Newswire 7 months ago
Fresenius Medical Care Partners with Sarah Bush Lincoln to Provide Life-Sustaining Care to Rural Patients

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases has launched an on-site dialysis program with Sarah Bush Lincoln, a regional health system in Mattoon, IL. This program now provides dialysis services with the NxStage VersiHD home hemodialysis system to patients in the local community who previously had to travel 100 miles to receive care. By keeping patients at the local hospital, the doctors and nurses have visibility to all other

PR Newswire 8 months ago
Fresenius Medical Care successfully executes strategic plan and narrows guidance range due to strong operational performance in the first half of 2023

Helen Giza, Chief Executive Officer of Fresenius Medical Care, said: "The second quarter makes evident that the execution against our strategic plan is fully on track. We are executing on our portfolio optimization, continuing to deliver on our FME25 program and are accelerating our turnaround activities. As expected, we have seen a stabilization of the labor market and of the inflationary environment. Our measures to increase productivity, supported by the targeted clinic closures, are driving

PR Newswire 8 months ago
Fresenius Medical Care simplifies corporate structure by converting into a German stock corporation

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, held an Extraordinary General Meeting (EGM) today. The Company's shareholders approved all agenda items with large majority, including the conversion of Fresenius Medical Care from the legal form of a partnership limited by shares (Kommanditgesellschaft auf Aktien, KGaA) into a German stock corporation (Aktiengesellschaft, AG), and elected the four shareholder representatives on the

PR Newswire 9 months ago
Fresenius Medical Care appoints Martin Fischer as Chief Financial Officer

Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases has appointed Martin Fischer (46) as Chief Financial Officer as of October 1, 2023. He will succeed Helen Giza who was appointed as Chief Executive Officer and Chair of the Management Board in December 2022 and continues to serve as acting Chief Financial Officer, until her successor will join. Martin Fischer will be based in Bad Homburg, Germany and will assume responsibility for th

PR Newswire 9 months ago

Performance Overview

Return	FME.BE	DAX PERFORMANCE-INDEX
YTD	+2.48%	+7.36%
1-Year	-5.72%	+13.37%
3-Year	-36.13%	+17.71%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Fresenius Medical Care AG & Co. KGaA (FME.BE)

Fresenius Medical Care publishes 2023 joint Annual Report and Sustainability Report: Shaping the Future of Kidney Care

Fresenius Medical Care launches "Augmented Reality" for training on Kidney Replacement Therapy device

Fresenius Medical Care Achieves Next Milestone in Portfolio Optimization Program, Announcing Sale of Dialysis Clinics in Brazil, Colombia, Chile, Ecuador

Fresenius Medical Care delivers on commitments in a year of fundamental transformation

Fresenius Medical Care Brings Industry-Leading Dialysis Therapy to Kidney Disease Patients in the U.S., demonstrating Global Leadership in Medical Device and Membrane Engineering Technologies

Fresenius Medical Care AG nominates Six Employee Representatives to the Supervisory Board

Fresenius Medical Care Executes on Its Strategic Portfolio Optimization Program and Announces Key Transactions

Fresenius Medical Care completes change of legal form into a German stock corporation

Fresenius Medical Care enters into favorable settlement agreement with U. S. government with positive earnings impact of approx. EUR 175 million - 2023 earnings outlook raised

Fresenius Medical Care continues to execute on turnaround plan and raises 2023 earnings outlook due to strong operational performance in first nine months and solid business outlook for the fourth quarter

Fresenius Medical Care appoints Craig Cordola as new Management Board member for Care Delivery

Fresenius Medical Care Demonstrates Commitment to Innovating Dialysis and Kidney Disease Care with Presentations at the American Society of Nephrology (ASN) Kidney Week 2023

Fresenius Medical Care Achieves Key AI Milestone With First-Phase Completion of Largest Global Dialysis Clinical Dataset

Capital Square Delivers 149.59% Total Return* to Investors in Medical Building DST

Capital Square Delivers 147.63% Total Return* to Investors in Medical Building DST

Fresenius Medical Care Announces FDA Clearance of Versi®HD with GuideMe Software

Fresenius Medical Care Partners with Sarah Bush Lincoln to Provide Life-Sustaining Care to Rural Patients

Fresenius Medical Care successfully executes strategic plan and narrows guidance range due to strong operational performance in the first half of 2023

Fresenius Medical Care simplifies corporate structure by converting into a German stock corporation

Fresenius Medical Care appoints Martin Fischer as Chief Financial Officer

Performance Overview